Pharma Companies Spend Billions More on Stock Buybacks Than Developing Drugs

House Oversight Committee report combats industry claims that lower drug prices would stifle innovation.


You can count on the Prospect, can we count on you?

There's no paywall here. Your donations power our newsroom as we report on ideas, politics and power — and what’s really at stake as we navigate another presidential election year. Please, become a member, or make a one-time donation, today. Thank you!